Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1594)	9/28/2005 2:46:48 PM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma downgraded to "market perform" - update Wednesday, September 28, 2005 12:40:24 PM ET Piper Jaffray NEW YORK, September 28 (newratings.com) - Analysts at Piper Jaffray downgrade MGI Pharma Inc (MOGN.NAS) from "outperform" to "market perform," while reducing their estimates for the company. The target price has been reduced from $30 to $25. In a research note published this morning, the analysts mention that the FY05 sales estimate for Aloxi has been reduced from $260 million to $250 million. The analysts expect Dacogen to receive the FDA approval in 2Q06. The EPS estimates for 2005 and 2006 have been reduced from $0.27 to $0.20 and from $0.59 to $0.40, respectively.

To: Icebrg who wrote (1594)	10/5/2005 7:05:01 AM
From: Icebrg	Read Replies (2) \| Respond to of 1826

MGI Pharma "outperform," target price reduced Wednesday, October 05, 2005 6:01:21 AM ET Robert W. Baird NEW YORK, October 5 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma Inc (MOGN.NAS), while reducing their estimates for the company. The target price has been reduced from $35 to $30. In a research note published this morning, the analysts mention that the downward revision in the estimates is to reflect the company's updated guidance, following the closing of the Guilford acquisition and higher share count. The healthy sales of MGI Pharma's Aloxi drug and the expected launch of Dacogen in early-2006 would drive the company's stock performance going forward, Robert W Baird adds. The EPS estimates for 2005 and 2006 have been reduced from $0.46 to $0.35 and from $0.85 to $0.62, respectively.